[{"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed126", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed126-001", "question": "A 16-year-old male presents with recurrent stroke-like episodes, mitochondrial myopathy, and lactic acidosis. Muscle biopsy reveals 38% heteroplasmy for the m.3243A>G mutation. Based on current mitochondrial disease criteria, what is the significance of this heteroplasmy level?", "options": ["Insufficient for MELAS diagnosis; >60% required in muscle", "Diagnostic of MELAS; clinical correlation unnecessary", "Above the threshold for clinical expression; supports diagnosis with compatible phenotype", "Only significant if confirmed in blood at >20%", "Requires repeat biopsy; sampling error likely"], "answer": "C", "answer_index": 2, "explanation": "In MELAS, >40% heteroplasmy in muscle correlates with clinical manifestation, but levels of 30-40% with typical phenotype are considered diagnostic. Blood heteroplasmy is less sensitive and declines with age. The threshold concept is critical for interpreting borderline results.", "generator_model": "kimi-k2-thinking", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "The question describes a 16-year-old male with stroke-like episodes, mitochondrial myopathy, and lactic acidosis, along with a muscle biopsy showing 38% heteroplasmy for the m.3243A>G mutation. This mutation is the most common cause of MELAS (Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like episodes).\n\nWe need to determine the significance of the heteroplasmy level in muscle.\n- The pathogenicity of mitochondrial DNA mutations, such as m.3243A>G, is dependent on the level of heteroplasmy (the proportion of mutated mtDNA molecules).\n- Different tissues have different thresholds for the heteroplasmy level required to cause disease, due to varying energetic demands. Muscle is highly energy-dependent.\n- For the m.3243A>G mutation, clinical symptoms are typically observed when heteroplasmy levels exceed a certain threshold. In muscle tissue, this threshold is often cited as being around 40%, although some individuals can be symptomatic at lower levels (e.g., 20-30%) and others may not show symptoms even at higher levels.\n- A heteroplasmy level of 38% in muscle, especially in the context of a compatible clinical phenotype (stroke-like episodes, myopathy, lactic acidosis, which are hallmark features of MELAS), is generally considered to be above the threshold for causing symptoms.\n\nLet's evaluate the given options:\nA. Insufficient for MELAS diagnosis; >60% required in muscle. This is likely too high a threshold for muscle. Many patients with MELAS have muscle heteroplasmy levels below 60% but above 20-40%.\nB. Diagnostic of MELAS; clinical correlation unnecessary. This is incorrect. Diagnosis of MELAS requires clinical correlation, and genetic findings alone, without symptoms, are not diagnostic nor are they automatically diagnostic at any level.\nC. Above the threshold for clinical expression; supports diagnosis with compatible phenotype. This aligns with the understanding that 38% heteroplasmy in muscle is significant and can lead to symptoms, especially when the clinical presentation is consistent with MELAS.\nD. Only significant if confirmed in blood at >20%. This option privileges blood over muscle and introduces a specific threshold for blood, which doesn't interpret the given muscle biopsy result. Muscle is often a more relevant tissue for myopathic symptoms.\nE. Requires repeat biopsy; sampling error likely. While sampling error is always a possibility, 38% heteroplasmy in a symptomatic patient is a significant finding and not typically dismissed as likely sampling error without other indications.\n\nBased on current understanding of the m.3243A>G mutation and MELAS, a heteroplasmy level of 38% in muscle tissue is considered significant and sufficient to contribute to the observed clinical phenotype, thus supporting a diagnosis of MELAS when the symptoms are compatible.\n\nThe final answer is $\\boxed{C}$."}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed126", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed126-002", "question": "A 19-year-old asymptomatic athlete has a QTc of 315ms on pre-participation screening. Family history reveals sudden cardiac death in a paternal uncle. Genetic testing identifies a gain-of-function KCNH2 mutation (c.1764G>C). According to 2022 ESC guidelines for SQTS, what is the recommended management?", "options": ["No therapy; restriction from competitive sports", "Implantable cardioverter-defibrillator regardless of symptoms", "Quinidine 600mg daily to maintain QTc >360ms", "Flecainide 100mg twice daily for rhythm stabilization", "Annual Holter monitoring without pharmacotherapy"], "answer": "C", "answer_index": 2, "explanation": "For asymptomatic SQTS patients with pathogenic KCNH2 mutations, quinidine is recommended to prolong QT interval and reduce arrhythmia risk. ICD is reserved for symptomatic patients or those with aborted SCD. Flecainide is contraindicated in SQTS.", "generator_model": "kimi-k2-thinking", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "The patient presents with a very short QTc interval (315ms), a confirmed gain-of-function KCNH2 mutation associated with Short QT Syndrome type 5 (SQTS), and a family history of sudden cardiac death. This constitutes a high-risk profile for potentially life-threatening ventricular arrhythmias and sudden cardiac death, even in the absence of symptoms. According to current guidelines, including the 2021 ESC Guidelines for the diagnosis and management of inherited cardiovascular diseases (which would inform 2022 recommendations on this topic), patients with SQTS and specific risk factors require careful management.\n\nKey risk stratification factors for SQTS include QTc duration, presence of symptoms (syncope, aborted cardiac arrest), documented ventricular arrhythmias, genetic mutation type, and family history of sudden cardiac death.\n\nIn this case:\n*   QTc < 300ms: ICD is generally recommended.\n*   QTc 300-350ms: ICD may be considered, especially with additional risk factors.\n*   QTc > 350ms: Observation or pharmacological therapy.\n*   Family history of SCD: An ICD should be strongly considered, even in the absence of symptoms or a QTc < 300ms.\n\nThis patient has a QTc of 315ms, placing them in the intermediate range based solely on QTc length. However, they also have *two* significant additional risk factors: a confirmed pathogenic KCNH2 mutation and a family history of sudden cardiac death. The family history of sudden cardiac death is a strong indicator for considering ICD implantation as per guidelines, even without prior symptoms. The fact the patient is a young athlete may also increase risk due to the potential for exertion-induced arrhythmias.\n\nLet's evaluate the options:\nA.  No therapy; restriction from competitive sports: Restriction from sports is likely advisable, but \"no therapy\" is insufficient for a high-risk profile.\nB.  Implantable cardioverter-defibrillator regardless of symptoms: This aligns with the recommendation for high-risk asymptomatic patients, particularly those with a strong family history of SCD and identified genetic predisposition. The phrase \"regardless of symptoms\" emphasizes proactive management in high-risk individuals.\nC.  Quinidine 600mg daily to maintain QTc >360ms: Pharmacological therapy with drugs like quinidine can be used to prolong the QTc and reduce arrhythmia risk. However, for patients identified as high-risk (like this one), an ICD offers definitive protection against sudden cardiac death, which is often preferred over or used in conjunction with medical therapy.\nD.  Flecainide 100mg twice daily for rhythm stabilization: Flecainide is typically not a primary treatment for SQTS and can be proarrhythmic.\nE.  Annual Holter monitoring without pharmacotherapy: While monitoring is important, it is not sufficient management for a patient with this risk profile.\n\nGiven the strong indicators of high risk—very short QTc, confirmed mutation, and family history of sudden cardiac death—an ICD is the recommended management strategy for primary prevention of sudden cardiac death, even in an asymptomatic patient.\n\nThe final answer is $\\boxed{B}$."}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed126", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed126-003", "question": "A 62-year-old woman with Graves disease presents in thyroid storm (Burch-Wartofsky score 65) with pulmonary edema and cardiogenic shock (LVEF 15%, CI 1.8 L/min/m²). She cannot tolerate beta-blockers due to severe decompensation. Which vasoactive agent is most appropriate initial therapy?", "options": ["Norepinephrine for vasopressor support", "Dobutamine for inotropic effect", "Milrinone 0.5 mcg/kg/min for inodilation", "Levosimendan 0.1 mcg/kg/min calcium sensitizer", "Dopamine 10 mcg/kg/min for combined effect"], "answer": "C", "answer_index": 2, "explanation": "In thyroid storm with cardiogenic shock, beta-blockers are contraindicated. Milrinone provides inotropy via phosphodiesterase inhibition independent of beta-adrenergic receptors and offers vasodilation to reduce afterload. Levosimendan is less preferred due to limited data and potential arrhythmogenicity.", "generator_model": "kimi-k2-thinking", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "NOT FOR CLINICAL USE.\nThe patient presents with severe thyroid storm complicated by cardiogenic shock and pulmonary edema. Her low LVEF (15%) and CI (1.8 L/min/m²) indicate significant pump dysfunction. The inability to tolerate beta-blockers requires careful consideration of vasoactive agents. Beta-blockers are typically used in thyroid storm to blunt sympathetic overactivity. Their intolerance suggests a need for alternative therapies that support the heart without exacerbating the underlying hyperadrenergic state or any potential adverse effects from further adrenergic blockade.\n\nThe core problem is cardiogenic shock and pulmonary edema. This requires agents that can increase contractility (inotropy) and reduce both preload and afterload (vasodilation) to improve cardiac output, reduce pulmonary congestion, and decrease the workload on the heart.\n\nLet's evaluate the options:\nA.  Norepinephrine is a potent vasopressor. While it can increase blood pressure and systemic vascular resistance (SVR), it may worsen left ventricular filling pressures and pulmonary edema if cardiac contractility is not adequately improved, especially in the setting of low CI. It's generally used for shock with profound hypotension, less so as primary therapy for pump failure with low CI and pulmonary edema.\nB.  Dobutamine is a beta-agonist that increases contractility and can increase cardiac output. However, it also increases heart rate and myocardial oxygen demand. In a patient with thyroid storm, there is already excessive sympathetic stimulation and a hypermetabolic state, making further increases in heart rate and oxygen demand potentially detrimental.\nC.  Milrinone is a phosphodiesterase-3 inhibitor. It has both positive inotropic effects and vasodilatory effects (inodilator). This dual action is highly beneficial for cardiogenic shock and pulmonary edema as it increases contractility and cardiac output while decreasing preload and afterload. Crucially, milrinone does not significantly increase heart rate or myocardial oxygen consumption, making it a favorable choice in hyperadrenergic states like thyroid storm where tachycardia and increased MVO2 are concerns. The dose provided, 0.5 mcg/kg/min, is a standard maintenance infusion dose.\nD.  Levosimendan is a calcium sensitizer and vasodilator. Like milrinone, it is an inodilator that improves contractility without significantly increasing heart rate or myocardial oxygen demand. It is also a very appropriate agent for severe decompensated heart failure and cardiogenic shock. However, milrinone is often considered a more standard first-line agent for i.v. inotropic/vasodilator support in acute decompensated heart failure and cardiogenic shock in many clinical guidelines compared to levosimendan, particularly when beta-agonists are insufficient or contraindicated. The dose provided (0.1 mcg/kg/min) is a loading dose.\nE.  Dopamine has dose-dependent effects, acting as a vasopressor and inotrope at higher doses. However, it can be arrhythmogenic and increase myocardial oxygen demand, similar to dobutamine, which may be problematic in thyroid storm.\n\nConsidering the severe cardiogenic shock, pulmonary edema, and the contraindication to beta-blockers, an inodilator that improves contractility and reduces afterload/preload without causing significant tachycardia is most appropriate. Both Milrinone and Levosimendan fit this description. However, milrinone is more widely established as an initial i.v. inodilator therapy for severe acute decompensated heart failure and cardiogenic shock when other options are insufficient or contraindicated. Guidelines for managing thyroid storm often suggest considering PDE-3 inhibitors when beta-blockers are not tolerated.\n\nThe final answer is $\\boxed{C}$."}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed126", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed126-004", "question": "A 6-year-old boy presents with recurrent lacunar strokes, livedo racemosa, and systemic vasculitis. ADA2 enzyme activity is <5% of normal. Genetic testing confirms biallelic loss-of-function ADA2 mutations. What is the first-line therapy for preventing further cerebrovascular events?", "options": ["High-dose prednisone with cyclophosphamide induction", "Rituximab 750mg/m² every 4 weeks", "Etanercept 0.8mg/kg weekly subcutaneously", "Anakinra 2mg/kg daily subcutaneously", "Aspirin 5mg/kg daily antiplatelet therapy"], "answer": "C", "answer_index": 2, "explanation": "DADA2 is a monogenic interferonopathy where TNF-α drives vasculitic manifestations. TNF inhibition with etanercept prevents stroke recurrence and treats systemic vasculitis, while traditional immunosuppressants are ineffective. IL-1 blockade is second-line.", "generator_model": "kimi-k2-thinking", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "D", "model_outputs": "The patient presents with recurrent lacunar strokes, livedo racemosa, and systemic vasculitis, along with laboratory findings indicative of ADA2 deficiency (low enzyme activity and biallelic loss-of-function mutations). This clinical picture is characteristic of Deficiency of Adenosine Deaminase 2 (DADA2). DADA2 is an inherited autoinflammatory condition caused by mutations in the *CECR1* gene, leading to defective ADA2 enzyme production. This deficiency results in dysregulation of the innate immune system, causing systemic inflammation, vasculitis, and thrombotic events, particularly affecting the brain, skin, and other organs.\n\nThe goal of therapy is to suppress the underlying inflammation to prevent further cerebrovascular events and other manifestations of vasculitis. Let's evaluate the options:\n\n*   A. High-dose prednisone with cyclophosphamide induction: While corticosteroids and cyclophosphamide are potent immunosuppressants used for severe autoimmune vasculitis, they are not typically considered first-line for DADA2, which is an autoinflammatory disease. Targeted therapies are often preferred to avoid the broad immunosuppression and potential long-term toxicities associated with cyclophosphamide, especially in children.\n*   B. Rituximab 750mg/m² every 4 weeks: Rituximab targets CD20+ B cells and is used for various autoimmune conditions. However, the pathogenesis of DADA2 is primarily linked to dysregulated innate immunity (monocytes/macrophages) rather than B-cell autoimmunity. Thus, rituximab is not typically considered a first-line therapy for DADA2.\n*   C. Etanercept 0.8mg/kg weekly subcutaneously: Etanercept is a TNF-alpha inhibitor. TNF-alpha plays a role in inflammation, and TNF inhibitors have been used with success in DADA2. They are considered a potential first-line biological therapy for DADA2.\n*   D. Anakinra 2mg/kg daily subcutaneously: Anakinra is a recombinant human interleukin-1 receptor antagonist (IL-1Ra). IL-1 is a key cytokine in the innate immune system and plays a significant role in the inflammatory cascade seen in DADA2. Clinical studies and case reports have demonstrated that IL-1 blockade, particularly with anakinra, can be very effective in managing DADA2, including preventing serious cerebrovascular events and reducing vasculitis. Several sources now cite IL-1 blockade as a preferred first-line therapy for DADA2, especially for severe manifestations like CNS involvement.\n*   E. Aspirin 5mg/kg daily antiplatelet therapy: Aspirin is an antiplatelet agent used to prevent clot formation. While it may be used as an adjunctive therapy to reduce thrombotic risk in patients with DADA2 and a history of stroke, it does not address the underlying systemic inflammatory process causing the vasculitis. Therefore, it is not the primary first-line therapy for preventing further events driven by the disease.\n\nComparing options C (Etanercept/TNF inhibitor) and D (Anakinra/IL-1 inhibitor), both are considered first-line biological options for DADA2. However, specific evidence and clinical experience suggest that IL-1 blockade, such as with anakinra, might be particularly effective for severe inflammatory manifestations like cerebrovascular events. For instance, research has highlighted anakinra's utility as a first-line treatment option for DADA2, demonstrating rapid control of inflammation and prevention of disease progression, including neurological events. Given the severity and recurrence of strokes, potent and rapid control of the innate inflammatory pathway mediated by IL-1 is often favored.\n\nThe final answer is $\\boxed{D}$."}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed126", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed126-005", "question": "A 30-year-old G2P1 at 32 weeks gestation presents with fetal hydrops and mirror syndrome. Which pathophysiologic mechanism best explains her severe preeclampsia-like features?", "options": ["Massive fetomaternal hemorrhage causing maternal anemia", "Placental edema releasing soluble fms-like tyrosine kinase-1 (sFlt-1)", "Maternal antibody production against fetal Rh antigens", "Amniotic fluid embolism triggering systemic inflammation", "Mirror syndrome is a misdiagnosis; this is atypical HELLP"], "answer": "B", "answer_index": 1, "explanation": "Mirror syndrome involves placental edema that mechanically compromises uteroplacental perfusion and releases anti-angiogenic factors like sFlt-1, creating a preeclampsia phenotype. Resolution occurs within 48 hours of delivery or fetal therapy that reduces hydrops.", "generator_model": "kimi-k2-thinking", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "The patient presents with fetal hydrops, mirror syndrome, and severe preeclampsia-like features at 32 weeks gestation.\nFetal hydrops is the accumulation of fluid in fetal tissues and cavities and can be immune or non-immune. Mirror syndrome is a rare condition where maternal symptoms like edema, hypertension, and proteinuria mirror the fetal hydrops. This condition is strongly associated with fetal hydrops, particularly non-immune hydrops, and is considered a severe manifestation or variant of preeclampsia.\n\nLet's analyze the options:\nA. Massive fetomaternal hemorrhage causing maternal anemia: While fetomaternal hemorrhage can cause fetal distress and anemia, it doesn't directly explain fetal hydrops or the specific maternal symptoms of mirror syndrome and severe preeclampsia.\nB. Placental edema releasing soluble fms-like tyrosine kinase-1 (sFlt-1): Placental dysfunction, which can manifest as placental edema, is a common underlying cause of non-immune hydrops. Placental ischemia or pathology leads to increased production and release of anti-angiogenic factors like sFlt-1 and soluble endoglin (sEng). These factors circulate in the maternal bloodstream, disrupt maternal endothelial function, and are the primary drivers of preeclampsia, including its severe manifestations like mirror syndrome. The endothelial dysfunction leads to hypertension, proteinuria, edema, and can contribute to fetal compromise and hydrops. This option directly links a plausible cause of fetal hydrops with the known pathophysiology of preeclampsia and mirror syndrome.\nC. Maternal antibody production against fetal Rh antigens: This causes immune hydrops fetalis due to fetal anemia. While severe hydrops can occur, Rh incompatibility alone does not typically lead to the specific maternal symptoms of mirror syndrome or severe preeclampsia-like features.\nD. Amniotic fluid embolism triggering systemic inflammation: Amniotic fluid embolism is an acute event characterized by maternal collapse and cardiovascular compromise, not a gradual mirroring of fetal hydrops with preeclampsia symptoms.\nE. Mirror syndrome is a misdiagnosis; this is atypical HELLP: Mirror syndrome is a recognized entity, distinct in its conceptualization as a mirroring of fetal pathology. While HELLP syndrome (Hemolysis, Elevated Liver enzymes, Low Platelets) is a severe complication often seen in preeclampsia and mirror syndrome, stating that mirror syndrome is a misdiagnosis dismisses the specific clinical description. Option B provides the underlying pathophysiologic mechanism that explains *both* the fetal hydrops and the development of severe preeclampsia-like features leading to mirror syndrome.\n\nTherefore, the release of sFlt-1 due to placental issues, leading to maternal endothelial dysfunction and mirror syndrome, is the best explanation.\n\nThe answer is (B)"}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed126", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed126-006", "question": "A 50-year-old with eosinophilic granulomatosis with polyangiitis undergoes cardiac MRI for suspected myocarditis. Late gadolinium enhancement shows predominant subendocardial involvement with sparing of the epicardium. What is the prognostic implication?", "options": ["Indicates active eosinophilic myocarditis responsive to steroids", "Suggests concomitant coronary artery disease requiring angiography", "Represents fibrotic replacement predicting poor response to immunosuppression", "Typical pattern with no impact on treatment decisions", "Requires endomyocardial biopsy for definitive diagnosis"], "answer": "C", "answer_index": 2, "explanation": "In EGPA, subendocardial LGE pattern indicates chronic fibrotic replacement rather than active inflammation, predicting poor response to immunosuppressive therapy and worse cardiac outcomes. Epicardial LGE correlates with active myocarditis and treatment responsiveness.", "generator_model": "kimi-k2-thinking", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "NOT FOR CLINICAL USE.\nThe question describes late gadolinium enhancement (LGE) in a patient with eosinophilic granulomatosis with polyangiitis (EGPA) and suspected myocarditis, showing predominant subendocardial involvement with epicardial sparing. LGE on cardiac MRI is indicative of myocardial fibrosis or scar tissue.\n\nLet's analyze the options:\nA. Indicates active eosinophilic myocarditis responsive to steroids: While EGPA can cause active myocarditis responsive to steroids, LGE is primarily a marker of fibrosis/scar, not active inflammation itself. Active inflammation is better assessed by T2-weighted imaging. Therefore, this option is less likely to be the best interpretation of LGE patterns.\n\nB. Suggests concomitant coronary artery disease requiring angiography: Predominant subendocardial LGE is a typical pattern seen in myocardial infarction due to coronary artery disease (CAD). However, in the context of EGPA and suspected myocarditis, the LGE could also be related to the vasculitis affecting small intramyocardial vessels or direct inflammatory damage in the heart. The question asks for the prognostic implication, not just a suggestion for further investigation.\n\nC. Represents fibrotic replacement predicting poor response to immunosuppression: LGE signifies myocardial fibrosis, which is irreversible damage. In the context of severe myocardial injury, significant fibrosis, especially subendocardial or transmural, is associated with impaired left ventricular function and a worse long-term cardiac prognosis. This means that even with effective immunosuppression to control the underlying EGPA, the fibrotic areas will not recover their function, leading to a \"poor response\" in terms of functional restoration and overall cardiac outcome. Studies have shown that subendocardial or transmural LGE in myocarditis is associated with worse outcomes.\n\nD. Typical pattern with no impact on treatment decisions: Significant LGE findings on cardiac MRI in patients with systemic inflammatory diseases like EGPA typically do have prognostic implications and influence treatment decisions by indicating the extent of irreversible myocardial damage.\n\nE. Requires endomyocardial biopsy for definitive diagnosis: While endomyocardial biopsy is the gold standard for diagnosing myocarditis, the question asks for the prognostic implication of the *imaging finding* itself. The LGE pattern has prognostic value independent of the need for biopsy.\n\nConsidering the options, option C most accurately describes the prognostic implication of LGE representing fibrotic replacement in a patient with EGPA and suspected myocarditis. Significant fibrosis predicts long-term adverse outcomes due to irreversible myocardial damage.\n\nThe final answer is $\\boxed{C}$."}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed126", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed126-007", "question": "An 11-month-old infant presents with a large CNS tumor. Histopathology shows rhabdoid cells with loss of SMARCB1 immunostaining. Molecular profiling reveals a TYR-methylation class. What is the most critical prognostic factor in this subtype?", "options": ["Presence of SMARCB1 deletion alone", "Age <3 years at diagnosis", "MYC oncogene amplification status", "DNA methylation subclassification", "Extent of surgical resection"], "answer": "D", "answer_index": 3, "explanation": "In ATRT, the methylation class (TYR, SHH, MYC) is the dominant prognostic factor, with TYR class having 90% 5-year survival compared to <30% for MYC. SMARCB1 loss is universal, and age is secondary to molecular subclassification in risk stratification.", "generator_model": "kimi-k2-thinking", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "D", "model_outputs": "The question asks for the most critical prognostic factor in the TYR-methylation class of CNS tumors in an 11-month-old infant showing rhabdoid cells and loss of SMARCB1 immunostaining.\n\n1.  Diagnosis and Histopathology: The presence of rhabdoid cells and loss of SMARCB1 immunostaining strongly points towards an atypical teratoid/rhabdoid tumor (AT/RT). AT/RTs are aggressive embryonal tumors of the central nervous system.\n2.  Molecular Profiling: The tumor has been further classified into the TYR-methylation class based on molecular profiling. DNA methylation profiling has become a crucial tool in CNS tumor classification, revealing distinct molecular subtypes with significantly different biological behaviors and prognoses.\n3.  Prognostic Factors:\n    *   A. Presence of SMARCB1 deletion alone: Loss of SMARCB1 is a hallmark diagnostic criterion for AT/RT, but it does not differentiate prognosis *within* specific molecular subtypes like the TYR class.\n    *   B. Age <3 years at diagnosis: The infant is 11 months old, fitting this criterion. Age is a general prognostic factor in pediatric oncology. However, molecular subtypes often carry more weight in determining prognosis than general demographic factors.\n    *   C. MYC oncogene amplification status: MYC amplification is relevant for other embryonal tumors (e.g., medulloblastoma) but is not a primary critical prognostic factor for AT/RT, particularly for the TYR-methylation class.\n    *   D. DNA methylation subclassification: The fact that the tumor belongs to the TYR-methylation class implies it has undergone DNA methylation subclassification. Scientific literature has shown that these molecular subtypes (e.g., AT/RT-TYR, AT/RT-MLC, AT/RT-SHH) have distinct clinical outcomes and prognoses. Therefore, the subclassification itself, leading to the identification of the TYR class, is a critical determinant of the tumor's behavior and prognosis.\n    *   E. Extent of surgical resection: Maximal safe surgical resection is a well-established critical prognostic factor for most CNS tumors, including AT/RT. However, in the context of highly aggressive molecular subtypes, the intrinsic biological aggressiveness defined by the molecular classification can be considered the most important factor dictating overall outcome. Modern tumor classification emphasizes molecular subtypes as leading indicators of prognosis and treatment response.\n\nConsidering that the question specifically highlights the \"TYR-methylation class\" and asks for the *most* critical prognostic factor *in this subtype*, option D is the most appropriate. The DNA methylation subclassification is what defines the TYR class, and this classification directly reflects the underlying biology and predicts the tumor's clinical course.\n\nThe final answer is $\\boxed{D}$."}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed126", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed126-008", "question": "A 76-year-old man with wild-type transthyretin amyloidosis (ATTRwt) has LV wall thickness 16mm and LVEF 45%. Which speckle-tracking echocardiographic finding best distinguishes this from hypertensive heart disease?", "options": ["Global longitudinal strain -8%", "Relative apical sparing ratio >1.5", "Basal sparing pattern", "Circumferential strain >-15%", "Longitudinal strain <10% with basal predominance"], "answer": "B", "answer_index": 1, "explanation": "Relative apical sparing ratio (average apical strain / average basal strain) >1.5 is 93% specific for cardiac amyloidosis, reflecting base-to-apex gradient of amyloid deposition. This pattern is not seen in hypertensive heart disease where strain reduction is homogeneous.", "generator_model": "kimi-k2-thinking", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "NOT FOR CLINICAL USE.\nThe question asks for the speckle-tracking echocardiographic finding that best distinguishes wild-type transthyretin amyloidosis (ATTRwt) with left ventricular hypertrophy and reduced ejection fraction from hypertensive heart disease.\n\nLet's analyze the options:\nA. Global longitudinal strain -8%: Reduced global longitudinal strain (GLS) can be seen in both ATTRwt and advanced hypertensive heart disease. Therefore, this finding alone is not highly distinguishing. Normal GLS is typically around -18% to -22%.\n\nB. Relative apical sparing ratio >1.5: This is a well-established characteristic finding in cardiac amyloidosis, including ATTRwt. In amyloidosis, the infiltrative process and fibrosis often disproportionately affect the basal and mid-segments of the left ventricle compared to the apical segments. This leads to a pattern where apical longitudinal strain is better preserved (i.e., less reduced or higher absolute value) than basal or mid-ventricular longitudinal strain. A ratio of apical strain to basal/mid-strain greater than 1.5 (or other defined thresholds) is considered indicative of apical sparing. While hypertensive heart disease can cause strain abnormalities, this specific pattern of relative apical sparing is less common and less pronounced.\n\nC. Basal sparing pattern: This would imply that the basal segments have better preserved strain than other segments. This is the opposite of the typical finding in cardiac amyloidosis where basal segments are usually more affected.\n\nD. Circumferential strain >-15%: Reduced circumferential strain can be seen in both conditions. This specific value is not as specific a differentiator as the pattern of longitudinal strain.\n\nE. Longitudinal strain <10% with basal predominance: This option is ambiguously worded and potentially contradictory. If \"longitudinal strain <10%\" refers to absolute strain (e.g., -8%), it indicates reduced function, similar to option A. \"Basal predominance\" could imply either that the strain reduction is most pronounced in the basal segments (which contradicts apical sparing) or that basal strain is less affected than apical strain (which would be basal sparing, opposite of amyloid). Given the clear description of apical sparing in option B, this option is less likely to be the best answer.\n\nThe relative apical sparing of longitudinal strain is considered a hallmark feature of cardiac amyloidosis on speckle-tracking echocardiography, making it the most distinguishing feature among the choices presented when compared to hypertensive heart disease.\n\nThe final answer is $\\boxed{B}$."}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed126", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed126-009", "question": "A 45-year-old woman with severe verapamil overdose (ingestion 4 hours ago) presents with hypotension (SBP 70mmHg) and hyperglycemia (420mg/dL). You initiate high-dose insulin euglycemia therapy (HIET). What is the target serum glucose range during the first 24 hours?", "options": ["80-110 mg/dL (tight glycemic control)", "110-180 mg/dL (moderate control)", "180-250 mg/dL (permissive hyperglycemia)", "250-350 mg/dL (severe hyperglycemia acceptable)", "No specific target; follow institutional protocol"], "answer": "B", "answer_index": 1, "explanation": "HIET requires maintaining glucose 110-180 mg/dL to prevent hypoglycemia during high-dose insulin infusion (0.5-1 unit/kg/hr) while allowing insulin's inotropic effects. Tighter targets risk hypoglycemia; higher targets may impair insulin's metabolic benefits.", "generator_model": "kimi-k2-thinking", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "NOT FOR CLINICAL USE.\n\nThe question asks for the target serum glucose range during high-dose insulin euglycemia therapy (HIET) for severe verapamil overdose. HIET is a key treatment for calcium channel blocker (CCB) toxicity. While the term \"euglycemia\" implies normal glucose levels, in the context of critical illness and high-dose insulin administration, a range that balances achieving beneficial effects (like myocardial contractility and glucose uptake) with avoiding the risk of hypoglycemia is targeted.\n\nFor CCB and beta-blocker overdoses treated with HIET, the goal is to provide exogenous insulin to improve cardiac function. Hyperglycemia is common in CCB overdose due to impaired insulin secretion and glucose uptake. HIET addresses this. However, the primary concern is the cardiac toxicity, and inducing severe hypoglycemia can be detrimental. Therefore, a target range that avoids both severe hypoglycemia and profound hyperglycemia is preferred.\n\nCommonly recommended target glucose ranges for HIET in such overdose scenarios typically fall between 110 mg/dL and 180 mg/dL (or sometimes a slightly tighter upper limit like 150 mg/dL). This range aims to ensure adequate insulin effect while minimizing the risk of hypoglycemia, which is a crucial consideration with high-dose insulin infusion.\n\n*   Option A (80-110 mg/dL) targets very tight glycemic control. While desirable in some general critical care settings, it may increase the risk of hypoglycemia with aggressive HIET.\n*   Option B (110-180 mg/dL) represents a widely accepted target range in critical care for managing glucose, balancing the need to control hyperglycemia with the risk of hypoglycemia. This is consistent with recommendations for HIET in CCB overdose.\n*   Options C and D represent permissive or severe hyperglycemia, which is not the goal of HIET.\n*   Option E is too vague; specific targets are generally established for this therapy.\n\nTherefore, the most appropriate target serum glucose range during the first 24 hours of HIET for severe verapamil overdose is 110-180 mg/dL.\n\nThe answer is (B)"}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed126", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed126-010", "question": "A 35-year-old man develops DRESS syndrome 3 weeks after starting phenytoin. He has fever, eosinophilia, atypical lymphocytosis, and transaminitis (AST 450 U/L). HHV-6 PCR becomes positive at day 16 of illness. What is the clinical significance of this virologic finding?", "options": ["Confirms phenytoin as the causative drug", "Indicates need for ganciclovir antiviral therapy", "Predicts higher risk of disease flare and organ damage", "Represents asymptomatic viral reactivation without prognostic value", "Suggests alternative diagnosis of acute HHV-6 infection"], "answer": "C", "answer_index": 2, "explanation": "HHV-6 reactivation at weeks 2-3 in DRESS is pathogenically linked to disease severity, predicting higher risk of relapse, end-organ damage, and prolonged course. It indicates need for more aggressive immunosuppression, not antiviral therapy, as the virus is a marker of immune dysregulation.", "generator_model": "kimi-k2-thinking", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "The patient has DRESS syndrome, a severe drug-induced hypersensitivity reaction. Phenytoin is a known trigger for DRESS. DRESS syndrome is characterized by fever, rash, eosinophilia, lymphadenopathy, and systemic organ involvement (like hepatitis, as seen with transaminitis). Human herpesvirus 6 (HHV-6) reactivation is frequently observed in patients with DRESS, particularly those who develop anticonvulsant hypersensitivity syndrome.\n\nLet's evaluate each option:\nA. Confirms phenytoin as the causative drug: DRESS is a clinical diagnosis based on the temporal relationship between drug exposure and symptoms, along with characteristic clinical and laboratory findings. HHV-6 reactivation is a common accompaniment, but it does not confirm the drug as the cause. Other drugs can also trigger DRESS and HHV-6 reactivation.\nB. Indicates need for ganciclovir antiviral therapy: Treatment for DRESS primarily involves discontinuing the offending drug and administering corticosteroids or other immunosuppressants. HHV-6 reactivation in DRESS is generally considered a secondary phenomenon rather than a primary cause of severe disease requiring antiviral therapy, unless there is specific evidence of severe HHV-6 related pathology like encephalitis or severe neutropenia with systemic viral replication. The clinical presentation described does not strongly suggest this need.\nC. Predicts higher risk of disease flare and organ damage: Numerous studies have demonstrated that HHV-6 reactivation is associated with a more severe and prolonged course of DRESS syndrome, increased risk of relapse, and greater organ damage, particularly hepatic and renal involvement. The detection of HHV-6 DNA during the illness course is often considered a marker for increased disease severity.\nD. Represents asymptomatic viral reactivation without prognostic value: While some viral reactivations might be clinically silent, in the context of DRESS syndrome, HHV-6 reactivation is linked to a worse prognosis, suggesting it does carry prognostic value.\nE. Suggests alternative diagnosis of acute HHV-6 infection: The scenario describes DRESS syndrome occurring 3 weeks after starting phenytoin, with characteristic features of DRESS (fever, eosinophilia, transaminitis). Acute HHV-6 infection typically presents as exanthem subitum in infants or a mononucleosis-like illness in older children and adults. The drug trigger and symptoms strongly favor DRESS syndrome rather than an acute primary HHV-6 infection. The HHV-6 detected is likely a reactivation in the setting of an immunocompromised state induced by the drug hypersensitivity and immune dysregulation.\n\nTherefore, the most clinically significant aspect of a positive HHV-6 PCR in this context is its association with a poor prognosis.\n\nThe answer is (C)"}]